exRNAdisease

General Information

Database ID:

exR0077313

RNA Name:

MYH9

RNA Type:

mRNA

Chromosome:

chr22

Starnd:

Coordinate:

Start Site(bp):

36281277

End Site(bp):

36388067

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABI2	chr2	203328239	203447728	+
ABLIM1	chr10	114431113	114768061	-
AC010616.1	chr19	41956879	41994232	-
AC018523.2	chr11	14493783	14520344	-
ACAD10	chr12	111686056	111757107	+
ACTA1	chr1	229431245	229434098	-
ACTB	chr7	5527148	5563784	-
ACTN4	chr19	38647649	38731589	+
ACTR1A	chr10	102461881	102502712	-
AD000671.1	chr19	35745678	35754519	+
ADAM19	chr5	157395534	157575775	-
ADCY6	chr12	48766194	48789037	-
ADGRE1	chr19	6887566	6940459	+
AK4	chr1	65147549	65232145	+
ALDH16A1	chr19	49453225	49471050	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-25-3p	chr7	100093571	100093592	-
hsa-miR-214-3p	chr1	172138816	172138837	-
hsa-miR-27b-3p	chr9	95085505	95085525	+
hsa-miR-185-5p	chr22	20033153	20033174	+
hsa-miR-485-5p	chr14	101055427	101055448	+
hsa-miR-650	chr22	22822791	22822811	+
hsa-miR-423-5p	chr17	30117095	30117117	+
hsa-miR-3609	chr7	98881700	98881723	+
hsa-miR-6819-3p	chr22	36286847	36286867	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC005899.4	chr17	32328441	32329395	+
AC016876.2	chr17	7581964	7584086	-
AC019080.1	chr2	177283508	177392691	-
AC026362.1	chr12	122975320	122982907	+
AC051619.7	chr15	45200325	45200632	-
AC106864.1	chr4	112693047	112706810	-
AC245014.3	chr1	145281116	145281462	+
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference